The commercial production of monoclonal antibodies (mAbs) has revolutionized the treatment of many diseases, including cancer, multiple sclerosis, and rheumatoid arthritis. These biotherapeutics have the potential to generate a global annual revenue of more than US$150 billion. Two cell hosts are predominantly utilized to produce these mAbs: Chinese hamster ovary (CHO) cells and murine myeloma cells (NS0). By 2017, nearly one-quarter of all approved mAbs in the market were produced using the NS0 host cell line, and around two-thirds were produced in CHO cells. Several different expression platforms are available: CHO-GS (glutamine synthetase), CHO-DHFR (dihydrofolate reductase), NS0, and GS-NS0, which have been characterized with respect to cell line and process development. Even though the major components of the cell culture media are common for both CHO and NS0 cells, specific growth media have been modified based on individual cellular requirements, such as cholesterol for NS0 cells. Additionally, understanding genomic and metabolic differences between the two cell hosts from an 'omics perspective has created a reference for media composition and antibody quality improvements.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-018-0319-9DOI Listing

Publication Analysis

Top Keywords

ns0 cells
12
cho ns0
8
cell hosts
8
cho cells
8
ns0
6
cells
6
cell
5
recombinant antibody
4
antibody production
4
cho
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!